Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02670980
NCT02670980CompletedNot Applicable

Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy

Pixium Vision SA9 sites in 5 countries10 target enrollmentStarted: January 1, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
10
Locations
9
Primary Endpoint
Number of participants with treatment-related adverse events according to ISO14155
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System (IRIS V2). Blind patient suffering from Retinitis Pigmentosa, Cone Rod Dystrophy, or Choroideremia are implanted with an Intelligent Retinal Implant Systeme. All subjects undergo ophthalmological examinations in predefined intervals after implantation. Ophthalmological examinations include funduscopy, slit lamp examination and OCT. All adverse events are recorded and analyzed. Efficacy is measured using functional vision and visual function tests before and after implantation as well as with the system on and system off.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
25 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Is 25 years or older at the date of enrolment
  • •Has a confirmed diagnosis of retinitis pigmentosa, choroideremia or cone-rod dystrophy
  • •Has a visual acuity of logMAR 2.3 or worse in both the eyes as determined by a Square Grating scale.
  • •Has functional ganglion cells and optic nerve activity
  • •Has a memory of former useful form vision
  • •Understands and accepts the obligation to present for all schedule follow-up visits.

Exclusion Criteria

  • •Has a history of severe glaucoma, uveitis, optic neuropathy or any confirmed damage to the optic nerve and/or visual cortex related to the projected implanted eye,
  • •Has any disease (other than study allowed diseases) or condition that affects retinal function of the study eye (e.g., central retinal artery/vein occlusion, end-stage diabetic retinopathy, current or prior retinal detachment, infectious or inflammatory retinal disease, etc.),
  • •Has any disease or condition that prevents adequate visualization of the retina of the study eye including, but not limited to, corneal degeneration that cannot be resolved prior to implantation,
  • •Has any disease or condition of the anterior segment of the study eye that prevents adequate physical examination (e.g., ocular trauma, etc.),
  • •Has severe nystagmus,
  • •Has any ocular condition that leads him or her to eye rubbing,
  • •Has any disease or condition that precludes the understanding or communication of the informed consent, study requirements or test protocols (e.g., deafness , multiple sclerosis, amyotrophic lateral sclerosis, neuritis, etc),
  • •Has a history of epileptic seizure,
  • •Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study,
  • •Has a known sensitivity to the contact materials of the implant (platinum and parylene),
  • •Presents with hypotony in the study eye,
  • •Presents with hypertony in the study eye,
  • •Is pregnant or lactating,
  • •Has another active implanted device (e.g. cochlear implant) or any form of metallic implant in the head (other than dental work) that may interfere with the device function,
  • •Has a diagnosis requiring an active implant (e.g., cardiac pacemaker, vagus nerve implant, etc.),
  • •Has active cancer or a history of intraocular, optic nerve or brain cancer and metastasis,
  • •Is an immune-suppressed subject (e.g., due to HIV positive diagnosis, etc.),
  • •Is carrier of multi-resistant germs,
  • •Requires the use of any of the following medications:
  • •Antimetabolites,
  • •Thrombocyte aggregation reducing therapies (10 days prior until 3 days after surgery),
  • •Oral anticoagulants (5 days before until 3 days after surgery),
  • •Is participating in another investigational drug or device study,
  • •Has any health concern that makes general anaesthesia inadvisable; Patients with an ASA-Score (or equivalent) of 3 or higher are excluded from the study,
  • •Is likely requiring MRI scans subsequent to implantation and prior to explantation,
  • •Is likely requiring therapeutic ultrasound subsequent to implantation and prior to explantation of the Retinal Implant.
  • •Patients with recurrent or chronic inflammations or infections are excluded from the study. Specifically patients with the following disorders are excluded:
  • •Common inflammation - severe chronic and consuming diseases that frequently associated with infection (e.g. Crohn disease, Whipple's disease)
  • •Chronic inflammation of the skin in the area of the eye (e.g. dermatitis, rosacea, infection of the skin, herpes zoster)
  • •Chronic inflammation in the area of the eye (e.g. herpes of cornea and/or conjunctiva, recurrent blepharoconjunctivitis, hordeolum, chalazion)
  • •Has a severe psychological disorder. When in any doubt, an expert assessment needs to be arranged to clarify whether the patient's psychological health is suitable for the trial.
  • •Has severe renal, cardiac, hepatic etc. organ diseases.
  • •Has eye AP dimension that are incompatible (less than 20.5 or larger than 25mm) with the implant or head dimension that are incompatible with the Visual Interface. Please make sure that the size of the eye socket allows an implantation of the extra ocular part which has a thickness of 5mm.

Arms & Interventions

Retina Implant

Experimental

Intelligent Retinal Implant System

Intervention: Intelligent Retinal Implant System (Device)

Outcomes

Primary Outcomes

Number of participants with treatment-related adverse events according to ISO14155

Time Frame: up to 36 month

All subjects undergo ophthalmological examinations in predefined intervals after implantation. Adverse event are rated to be serious or non-serious according ISO14155

Secondary Outcomes

  • Square localization(up to 36 month)
  • Functional Vision(up to 36 month)
  • Visual acuity(up to 36 month)

Investigators

Sponsor
Pixium Vision SA
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (9)

Loading locations...

Similar Trials

Completed
Not Applicable
Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal DystrophyRetinitis PigmentosaChoroideremiaCone Rod Dystrophy
NCT01864486Science Corporation20
Completed
Not Applicable
PRIMA US-Feasibility Study in Atrophic Dry AMDDry Age-related Macular Degeneration
NCT03392324Science Corporation5
Completed
Not Applicable
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular DegenerationDry Age-related Macular Degeneration
NCT03333954Science Corporation5
Unknown
Not Applicable
IRIS PILOT - Extended Pilot Study With a Retinal Implant SystemChoroideremiaRetinitis PigmentosaCone-Rod Dystrophy
NCT00427180Intelligent Medical Implants GmbH20
Withdrawn
Not Applicable
Argus II Retinal Prosthesis System - Better Vision RP StudyRetinitis Pigmentosa
NCT03418116Second Sight Medical Products
Compensation for Blindness With the... | Clinical Trial